CBCI

Congrats!!!

TIGIT study is currently enrolling for #myeloma and #lymphoma patients @ColoradoBlood #CBCI #TCTM20

There may be options after failure of CAR T-cell therapy. #CBCI is opening an anti CD20-CD3 therapy soon...stay tuned #lymphoma

Dr. Nash reviewed data for autologous transplant for multiple sclerosis and announced the exciting future phase 3 study (BEAT MS) which will not use CD34 Selection and it will be done in collbration with @BMTCTN

One of our @CBCIDocs, Dr Richard Nash, discussing the use of autologous HCT in the treatment of #MultipleSclerosis and other autoimmune diseases at #BMTTandem18

Caregiver support groups available @ColoradoBlood. A safe place for participants to discuss unique #BMT stressors twitter.com/bmtinfonet/sta…

Patients will tell other patients things they won't tell HCP or caregivers. #Mentoring is key. #NIHBMTLateEffects twitter.com/bldcancerdoc/s…

@CBCIDocs thank @ASH_hematology and all the amazing #lymphoma scientists for sharing novel research at #ASHMLB16. Great meeting!

More compelling pre-clinical data on the possible role of HDAC inhibition in #lymphoma #ASHMLB16

@CBCIDocs at @ASH_hematology #lymphoma biology conference in CBCI's beautiful backyard! #ASHMLB16 #keeprising

ASCO. Meta analysis shows revlimid maint emac after asct improves Overall survival dramatically

Dasatinib + Low-Intensity Chemo Results in Long-Term Survival for Older Patients with Ph+ ALL ow.ly/PevY300Y6p8 via @ASHClinicalNews

LLS Rocky Mountain Blood Cancer Conference today! Snowstorms can't keep away all our amazing patients. Thank you @llsusa @ColoradoBlood

FDA Grants Midostaurin Breakthrough Designation for AML shar.es/1CniVC via @OncLive #ASH15

Because of your support, these numbers continue to rise! #hodgkinlymphoma #SomedayisToday

Cord blood can be used to treat more than 80 diseases,including blood cancers like leukemia & lymphoma. Learn more: p.ctx.ly/r/1tpx

Porter: Relapsed ALL a great target for CAR T-cells #BMTTandem16

More than 8600 patients enrolled in @BMTCTN trials in 11 years!#BMTTandem16 #bmtsm @CIBMTR

@CIBMTR encouraging to see outcomes improving for patients 70+years who've had an allogeneic transplant #BMTTandem16 bit.ly/1T0Ewke